BRCC3
BRCC3 (BRCA1/BRCA2-containing complex subunit 3, also known as BRCC36, C6.1A and CXorf53) is a metalloprotease that specifically cleaves Lys-63-linked polyubiquitin chains. It acts in the DNA damage response, mitotic spindle assembly and innate immune signalling. Browse Assay Genie's current range of BRCC3 research reagents below, or read on for the biology behind the target.
BRCC3 is a metalloprotease that specifically cleaves Lys-63-linked polyubiquitin chains and has no activity toward Lys-48-linked chains. It is a component of the BRCA1-A complex, which recognises Lys-63-ubiquitinated histones H2A and H2AX at DNA lesion sites and helps target the BRCA1-BARD1 heterodimer to double-strand breaks. Within this complex BRCC3 removes Lys-63-linked ubiquitin from H2A and H2AX, antagonising RNF8-dependent ubiquitination at these sites. It also regulates the abundance of Lys-63-linked polyubiquitin chains in chromatin.
BRCC3 is the catalytic subunit of the BRISC complex, a multiprotein complex that cleaves Lys-63-linked ubiquitin from a range of substrates. BRISC mediates the Lys-63-specific deubiquitination associated with the COP9 signalosome through its interaction with that complex, and is required for normal mitotic spindle assembly and microtubule attachment to kinetochores through deubiquitination of NUMA1. BRCC3 also deubiquitinates IFNAR1, which increases its stability and cell surface expression and so supports interferon signalling; through this route it down-regulates the response to bacterial lipopolysaccharide. It deubiquitinates NLRP3 to promote NLRP3 inflammasome assembly, and deubiquitinates HDAC1 and PWWP2B, leading to their stabilisation.
The BRCC3 gene encodes a protein of the peptidase M67A family, BRCC36 subfamily, and belongs to the JAMM/MPN+ metallopeptidase family. The protein is found in the nucleus, the cytoplasm and at the spindle pole. NCBI notes that loss of the gene results in abnormal angiogenesis and is associated with syndromic moyamoya, a cerebrovascular angiopathy. Alternative splicing produces multiple transcript variants, and a related pseudogene exists on chromosome 5. Mouse and rat both carry a Brcc3 ortholog.
BRCC3 removes Lys-63-linked ubiquitin from histones H2A and H2AX at double-strand breaks, shaping how BRCA1-BARD1 is recruited to DNA lesions.
As a Lys-63-specific deubiquitinase with no activity toward Lys-48 chains, BRCC3 is a useful model for studying linkage-selective deubiquitination.
BRCC3 deubiquitinates IFNAR1 and NLRP3, linking it to interferon signalling, lipopolysaccharide responses and NLRP3 inflammasome assembly.
The BRISC complex deubiquitinates NUMA1, and is required for normal spindle assembly and microtubule attachment to kinetochores.
BRCC3 is a Lys-63-specific deubiquitinase. In the BRCA1-A complex it removes Lys-63-linked ubiquitin from histones H2A and H2AX at DNA double-strand breaks. As the catalytic subunit of the BRISC complex it also acts on substrates such as NUMA1, IFNAR1, NLRP3 and HDAC1.
BRCC3 stands for BRCA1/BRCA2-containing complex subunit 3. Aliases include BRCC36, C6.1A and CXorf53, the last reflecting its former name, chromosome X open reading frame 53. UniProt names the protein Lys-63-specific deubiquitinase BRCC36. NCBI notes that alternative splicing yields multiple transcript variants.
Mouse and rat each have a Brcc3 ortholog, so the gene is conserved across these species; check the datasheet of any product for its validated reactivity. According to NCBI, loss of BRCC3 results in abnormal angiogenesis and is associated with syndromic moyamoya, a cerebrovascular angiopathy.
BRCA1 complex partners, ubiquitin signalling proteins and innate immune targets that connect to BRCC3 biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P46736; product specifications from Assay Genie datasheets.